From: Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma
Study | NCT number (trial name) | Phase | Number | Regimen | ORR (%) | PFS rate (%) (1Â year) | OS rate (%) (1Â year) | Median PFS (months) |
---|---|---|---|---|---|---|---|---|
Clinical trials with daratumumab as monotherapy | ||||||||
Lokhorst et al. 2015 [22] | NCT00574288 (GEN501) | 1/2 | 30 | Daratumumab (8 mg/kg) | 10 | – | 77 | 2.4 |
42 | Daratumumab (16Â mg/kg) | 36 | 65 | 77 | 5.6 | |||
Lonial et al. 2016 [23] | NCT01985126 (SIRIUS) | 2 | 106 | Daratumumab (16 mg/kg) | 29 | – | 65 | 3.7 |
Clinical trials with daratumumab in combination regimens | ||||||||
Plesner et al. 2015 [27] | NCT01615029 | 1/2 | 32 | Daratumumab (16 mg/kg) + Rd | 88 | – | – | – |
Chari et al. 2015 [29] Mateos et al. 2015 [30] | NCT01998971 | 1 | 6 | Daratumumab (16 mg/kg) + VD | 100a | – | – | – |
11 | Daratumumab (16 mg/kg) + VTD | 100b | – | – | – | |||
8 | Daratumumab (16 mg/kg) + VMP | 100c | – | – | – | |||
77 | Daratumumab (16 mg/kg) + POM-D | 59d | – | – | – | |||
Palumbo et al. 2016 [32] | NCT02136134 (CASTOR) | 3 | 251 | Daratumumab (16 mg/kg) + VD | 83e | – | – | NRe |
247 | VD | 63e | – | – | 7.16e |